-
Fosun Pharma (02196.HK) expects full-year revenue of RMB 41.07 billion in 2024, compared to RMB 41.248 billion in the same period last year.
-
HAIDILAO (06862.HK): Achieved operating revenue of RMB 42.75 billion in 2024, a year-on-year increase of 3.1%.
-
Kuaishou (01024.HK): The AI large model is expected to reduce the production cost of customer short video marketing materials by 60-70%.
-
NONGFU SPRING (09633.HK): Full-year net profit for 2024 is expected to be RMB 12.12 billion, with market estimates at RMB 12.49 billion, and a full-year gross profit margin of 58.1%.
-
GREENLAND HK (00337.HK): Expected net loss for 2024 is between approximately RMB 1.8 billion and RMB 2.1 billion.
-
China Telecom (00728.HK): For the year ending December 31, 2024, the company's operating revenue is RMB 529.4 billion, a year-on-year increase of 3.1%.
-
China Merchants Bank (03968.HK): Achieved operating net income of RMB 337.121 billion in 2024, a year-on-year decrease of 0.58%; net profit of RMB 148.391 billion, a year-on-year increase of 1.22%.
-
CHINA CINDA (01359.HK): Total revenue for 2024 is approximately RMB 73.04 billion, a year-on-year decrease of 4.11%; net profit of RMB 3.0364 billion, a year-on-year decrease of 47.84%.
-
CHINA JINMAO (00817.HK): Achieved revenue of RMB 59.053 billion in 2024, with a net profit of approximately RMB 1.065 billion.
-
WuXi Biologics (02269.HK): Revenue for 2024 is RMB 18.6754 billion, a year-on-year increase of 9.6%; adjusted net profit of RMB 4.784 billion, a year-on-year increase of 1.8%.
-
CGN NEW ENERGY (01811.HK): Revenue of USD 1.951 billion, a year-on-year decrease of 11.02%; net profit of USD 248 million, a year-on-year decrease of 7.35%
